A pioneering trial of an interactive gaming technology designed to train individuals to consciously alter their own brain waves has demonstrated significant promise as a treatment for chronic nerve pain. The breakthrough, led by a team of researchers from UNSW Sydney, offers a glimpse into a future where debilitating neuropathic conditions could be managed through drug-free, non-invasive interventions performed in the comfort of a patient’s own home. Known as PainWaive, the technology represents a potential paradigm shift in pain management, particularly for those seeking alternatives to traditional pharmacological treatments such as opioids.
The PainWaive system was developed by researchers at UNSW Sydney’s NeuroRecovery Research Hub to address the underlying neurological imbalances associated with chronic nerve pain. By teaching users how to regulate abnormal brain activity, the technology aims to restore healthy communication between different regions of the brain. The results of a recent pilot study, published in the Journal of Pain, suggest that this form of neuromodulation could provide relief comparable to, or even exceeding, the efficacy of powerful painkillers.
Chronic nerve pain, or neuropathic pain, is notoriously difficult to treat. Unlike the acute pain resulting from a temporary injury, neuropathic pain is often the result of damage to the somatosensory nervous system. It is frequently described by patients as a burning, stabbing, or electric shock-like sensation that persists long after an initial injury has healed. For many, this leads to a cycle of chronic suffering, sleep deprivation, and a significant decline in quality of life. The current gold standard for treatment often involves high-dose opioids or anticonvulsants, both of which carry the risk of severe side effects, dependency, and diminishing returns over time.
The PainWaive project, led by Professor Sylvia Gustin and Dr. Negin Hesam-Shariati, seeks to break this cycle by targeting the source of the pain: the brain itself. The study followed participants over a four-week period, during which they engaged with the interactive game app while wearing a specialized electroencephalogram (EEG) headset. The research team tracked hundreds of individual measures, focusing not only on the intensity of the pain but also on "pain interference"—the degree to which the pain hindered the participants’ daily activities and emotional well-being.
The findings were striking. Three out of the four participants in the initial trial reported significant reductions in their pain levels, with the most substantial improvements occurring toward the final stages of the month-long treatment. For these individuals, the relief achieved through the PainWaive system was equal to or greater than the relief they had previously experienced through opioid medication.
Despite these encouraging outcomes, the researchers maintain a cautious and rigorous scientific perspective. Dr. Hesam-Shariati, a lead researcher on the study, noted that the small sample size is a factor that must be considered when interpreting the data. "Restrictions in the study’s size, design and duration limit our ability to generalise the findings or rule out placebo effects," she explained. However, she emphasized that the pilot was intended to establish proof-of-concept, and in that regard, it succeeded. "The results we’ve seen are exciting and give us confidence to move to the next stage and our larger trial."
The foundation of the PainWaive technology lies in years of seminal research conducted by Professor Sylvia Gustin into the thalamus. Located deep within the brain, the thalamus acts as a central relay hub, responsible for processing and transmitting sensory information to the cerebral cortex. Professor Gustin’s research identified that individuals suffering from chronic neuropathic pain often exhibit distinct, abnormal patterns in their brain waves, specifically within the thalamocortical circuit.
